Matteo Droghetti retweeted
Read European Urology Oncology's latest article published online, by Lorenzo Bianchi et al.
Thank you for your contribution!
Prostate-specific Membrane Antigen Positron Emission Tomography Versus Conventional Imaging for Preoperative Staging High-risk Prostate Cancer Patients Undergoing Surgery for cN0M0 Disease: An European Association of Urology—Young Academic Urologists Prostate Cancer Working Group Multi-institutional Study
Explore the full study at: euoncology.europeanurology.c…
@Lorenzo26232839
@drMDrog
@cal_Catanzaro
@MRoupret
@CaPsurvivorshop
@Ric_Campi
@jteoh_hk
@UroDocAsh
@Uroweb
@F_Montorsi
@Albert0Briganti
@ClaudiaKesch
@roodvdb
@riccardosciav6
@dr_rajwa
#UroOncology #ProstateCancer #MensHealth #eau #YAU #urologist
Matteo Droghetti retweeted
How important is knowledge of anatomy for the surgeons of the next gen? learn with the brightest young urologists and anatomists at the university of bologna
@Eugenio74446325
@aleantonellibs1
@minerviniandre
@agalfano
@pietropiazza
@paolo_delloglio
@GGandaglia
@RicBertolo
@andreamari08
@AngeloMottaran
@drMDrog
Matteo Droghetti retweeted
Catching up some reading & good to see initial conclusions confirmed in longer term results, that adj RT after RP doesn’t improve FFDM or OS & ⬆️ toxicity compared to salvage.
There is slight curve sep at 10 years for FFDM with p = 0.09 but seems unlikely to become clinically relevant.
secure.jbs.elsevierhealth.co…
Matteo Droghetti retweeted
1st Edition of the Italian #ESUBootCamp - It's a wrap!
A big thank you to all the trainees, the faculty, @UrowebESU @SIU_Italia @HUNIMED for making this a fantastic opportunity for young urology residents to gain hands-on training. #UrologyTraining
@NBuffi @tiago_urology
Matteo Droghetti retweeted
🔍 New study sheds light on prostate cancer treatment outcomes!
🤔While biochemical recurrence is more common post-radical prostatectomy, the mortality risk is higher post-radiotherapy.
🩺 Rethinking our approach to BCR is crucial to optimize patient care and reduce overtreatment. 🚫
#prostatecancer #ProstateCancerAwarenessMonth
@JAMANetworkOpen @OncoAlert @APCCC_Lugano @PCFnews @Tilki_De @piet_ost @AlbertoBossial @GGiannarini @Uromigos @urotoday @Uroweb @zklaassen_md @amerseburger
doi:10.1001/jamanetworkopen.2023.32900
Matteo Droghetti retweeted
“It’s unethical to prescribe ADT alone for metastatic prostate cancer”. Strong words from Urologist Prof Fred Saad on latest GU Cast. Also, “urologists shouldn’t dabble in metastatic prostate cancer”. Don’t be a dabbler! – at Melbourne, Victoria
Urologists take note! ARPIs getting reimbursed for mHSPC. GU Cast is back with with Fred Saad, @ciaraconduit @RenuEapen @declangmurphy
youtu.be/xNl2JIQN82k
Matteo Droghetti retweeted
In well selected patients - solitary tumors < 7 cm, no or unilateral hydronephrosis, minimal CIS - results with TMT are comparable to Radical Cystectomy
#patientchoice #bladdercancer #BladderCancerMonth23
thelancet.com/journals/lanon…
@TheLancetOncol @BladderCancerUS
Matteo Droghetti retweeted
Matteo Droghetti retweeted
🆕 Offer patients with cN1 disease a local treatment (either radical prostatectomy or IMRT/VMAT plus IGRT) plus long-term androgen-deprivation therapy.
#ProstateCancer #EAUguidelines
uroweb.org/guidelines/prosta…
Matteo Droghetti retweeted
New article (Vol. 183)
Brachytherapy boost improves survival and decreases risk of developing distant metastases compared to external beam radiotherapy alone in intermediate and high risk group prostate cancer patients
Marcin Miszczyk et al.
doi.org/10.1016/j.radonc.202…
Matteo Droghetti retweeted
Opinion: Open Science
Sentinel Lymph Node Biopsy: A Great Opportunity for Personalized Radiotherapy in Prostate Cancer buff.ly/3K8qKdT
@stephane_supiot
#prostatecancer
Matteo Droghetti retweeted
The last day of recruitment for STAMPEDE today - huge thanks to almost 12000 patients and over 5000 researchers. Thread below summarises some of the contributions we have made. It’s been a huge honour and privilege to lead this.
Our last cancer trial before #WorldCancerDay is STAMPEDE!
The #STAMPEDEtrial has been assessing multiple different treatment options for people with advanced or metastatic #ProstateCancer since 2005.
Its findings have improved the standard of care for advanced cancer🧵
Matteo Droghetti retweeted
Intermediate-risk Prostate Cancer—A Sheep in Wolf’s Clothing?
buff.ly/38128B0
@Freddie_Hamdy @MRoupret
#ESOU #MedTwitter #UroSoMe
Matteo Droghetti retweeted
Replying to @AzadOncology @PCF_Science @OncBrothers @OncoAlert @urotoday @neerajaiims @shilpaonc @LouiseKostos @gu_onc @EdmondMKwan @montypal @NazliDizman @PGrivasMDPhD @pfizer @DrMLChua
The ARTA mono being superior to ADT is something I would never expect. Opens opportunities in high risk localized PCa and de novo mHSPC.
Matteo Droghetti retweeted
EMBARK study exploring enzalutamide+ADT vs ADT/placebo vs enza mono in nmCS #ProstateCancer and high-risk BCR met the primary endpoint MFS. Sign. difference also between Enza mono vs ADT/. Curious to see OS, subsequent treatment, PRO data @SFreedlandMD @nealshore @marty_gleave
Matteo Droghetti retweeted
PSMA-PET for recurrent #ProstateCancer and guidance of salvage treatments: Is the sooner always the better? (“Shoot Blind” or “Sharpshooting”?). Presentation by @drMDrog @AlleConCancro. #EAU23 written coverage by @rksayyid @UofTUrology > https://nitter.cf/t.co/ksGwqdEFCa @Uroweb
Matteo Droghetti retweeted
Replying to @DrMHofman @Uroweb
Spectacular LuTectomy case with PSA 340 and 5cm lymph node. Excellent PSA and imaging response with straightforward surgery and PSA undetectable at one year #eau23 – at Milan, Lombardy











































